Advances in the management of multiple myeloma

Abstract

Outcomes for MM patients are improving as a result of the recently approved new agents including mAbs. Te place of these new drugs for the treatment of these patients as well as optimizing their use in combination with other efective anti-MM agents is the subject of many current clinical trials. Unfortunately, little remains known about the optimal sequencing or length of treatments for these patients; as more drugs become available, this will become even more difcult to sort out. Individualizing treatment for MM patients is also a goal for this disease so that patients can receive therapies based on the characteristics of their disease, immune system, and overall health, which should improve these patients' length and quality of life. Most importantly, these new treatments and learning that drugs can be re-used efectively and safely in new combinations have allowed patients to have an ever increasing number of options that have resulted in dramatic improvements in the quality and length of lives of our patients with MM.